Kite Pharma, Inc. (KITE): Jeffrey Wiezorek , SVP Clinical Development of Kite Pharma, Inc. sold 1,500 shares on Jul 1, 2016. The Insider selling transaction was reported by the company on Jul 5, 2016 to the Securities and Exchange Commission. The shares were sold at $50.01 per share for a total value of $75,007.35 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 27, 2016, Cynthia M Butitta (Chief Operating Officer) sold 20,000 shares at $50.71 per share price.On Jun 8, 2016, Roy Doumani (director) sold 14,000 shares at $58.06 per share price.Also, On Jun 2, 2016, Jeffrey Wiezorek (SVP Clinical Development) sold 3,000 shares at $51.04 per share price.On Mar 17, 2016, Rizwana F Sproule (VP Regulatory Affairs) sold 8,500 shares at $46.58 per share price.
Kite Pharma Inc: On Friday, Jul 1, 2016 heightened volatility was witnessed in Kite Pharma Inc which led to swings in the share price. The shares opened for trading at $49.98 and hit $51.01 on the upside , eventually ending the session at $50.95, with a gain of 1.90% or 0.95 points. The heightened volatility saw the trading volume jump to 7,40,873 shares. The 52-week high of the share price is $89.84 and the company has a market cap of $2,503 M . The 52-week low of the share price is at $38.41.
Company has been under the radar of several Street Analysts.Kite Pharma Inc is Initiated by Raymond James to Outperform and the brokerage firm has set the Price Target at $61. The Rating was issued on Jun 2, 2016.Kite Pharma Inc is Reiterated by Mizuho to Buy while Lowering the Price Target of the company shares to $ 80 from a previous price target of $90 . The Rating was issued on May 10, 2016.
Kite Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT) which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). It is conducting a Phase II clinical trial of a TCR-based therapy and multiple Phase I-IIa clinical trials of CAR- and TCR-based therapies. The Company’s lead product candidate KTE-C19 is a CAR-based therapy for the treatment of refractory diffuse large B cell lymphoma (DLBCL) primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is developing a pipeline of eACT-based product candidates for the treatment of advanced solid and hematological malignancies: CD19CAR KTE-C19CAR and EGFRvlll CAR among others.